View Older Stories View More Recent Stories

Nov 22, 2021 04:01PM Arrowhead Pharmaceuticals Reports Fiscal 2021 Year End Results
Nov 17, 2021 09:15AM Arrowhead Pharmaceuticals Inc. (ARWR) Announces JNJ-75220795 in Development for NASH (JNJ)
Nov 17, 2021 09:00AM Arrowhead Announces JNJ-75220795 in Development for NASH
Nov 15, 2021 01:00PM Arrowhead Collaborator Presents Phase 2b Clinical Data from REEF-1 Study in Patients with Chronic Hepatitis B Infection
Nov 15, 2021 07:30AM Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021
Nov 12, 2021 07:32AM Arrowhead Pharmaceuticals Inc. (ARWR) Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
Nov 12, 2021 07:30AM Arrowhead Presents Additional Clinical Data on Investigational ARO-HSD Treatment at AASLD Liver Meeting
Nov 12, 2021 07:30AM Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
Nov 1, 2021 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Year End Results
Nov 1, 2021 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences
Oct 25, 2021 07:30AM Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
Oct 12, 2021 04:00PM Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
Sep 30, 2021 07:40AM Arrowhead Pharmaceuticals Inc. (ARWR) Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
Sep 30, 2021 07:30AM Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
Sep 29, 2021 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences
Sep 28, 2021 07:31AM Arrowhead Pharmaceuticals Inc. (ARWR) Earns $10 Million Phase 1 Milestone Payment
Sep 28, 2021 07:30AM Arrowhead Earns $10 Million Phase 1 Milestone Payment
Sep 1, 2021 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
Aug 5, 2021 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results
Jul 29, 2021 07:47AM Arrowhead Pharmaceuticals Inc. (ARWR) Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Jul 29, 2021 07:30AM Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Jul 14, 2021 07:30AM Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 14, 2021 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results
Jul 6, 2021 07:31AM Arrowhead Pharmaceuticals (ARWR) Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of ccRCC
Jul 6, 2021 07:30AM Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Jul 2, 2021 07:32AM Arrowhead Pharmaceuticals Inc. (ARWR) Pauses ARO-ENaC Phase 1/2 Clinical Study
Jul 2, 2021 07:30AM Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
Jun 30, 2021 07:30AM Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
Jun 26, 2021 06:15AM Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
Jun 25, 2021 07:32AM Arrowhead Pharmaceuticals Inc. (ARWR) Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress
Jun 25, 2021 07:30AM Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress
Jun 23, 2021 07:32AM Arrowhead Pharma (ARWR) Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
Jun 23, 2021 07:30AM Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
Jun 21, 2021 07:32AM Arrowhead Pharmaceuticals (ARWR), Horizon Therapeutics (HZNP) Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 21, 2021 07:30AM Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 21, 2021 07:30AM Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 3, 2021 07:30AM Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
Jun 2, 2021 07:30AM  Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
May 18, 2021 07:34AM Arrowhead Pharmaceuticals (ARWR) Earns $10 Million Option Exercise Fee
May 18, 2021 07:30AM Arrowhead Earns $10 Million Option Exercise Fee
May 12, 2021 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
May 4, 2021 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results
Apr 28, 2021 07:36AM Arrowhead (ARWR) Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
Apr 28, 2021 07:30AM Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
Apr 16, 2021 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results
Apr 15, 2021 07:31AM Arrowhead Pharmaceuticals Inc. (ARWR) Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
Apr 15, 2021 07:30AM Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
Mar 1, 2021 07:40AM Arrowhead Pharmaceuticals Inc. (ARWR) Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
Mar 1, 2021 07:30AM Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
Jan 25, 2021 07:33AM Arrowhead Pharmaceuticals Inc. (ARWR) Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia
View More Recent Stories View Older Stories